Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
INTRODUCTION: We tested the hypothesis that the amyloid β (Aβ) peptide ratios are more stable than Aβ42 alone when biofluids are exposed to two preanalytical conditions known to modify measurable Aβ concentration.
METHODS: Human cerebrospinal fluid (CSF) and culture media (CM) from human cortical neurons were exposed to a series of volumes and polypropylene surfaces. Aβ42, Aβ40, and Aβ38 peptide concentrations were measured using a multiplexed electrochemiluminescence immunoassay. Data were analyzed using mixed models in R.
RESULTS: Decrease of measurable Aβ peptide concentrations was exaggerated in longer peptides, affecting the Aβ42:Aβ40 and Aβ42:Aβ38 ratios. However, the effect size of surface treatment was reduced in Aβ peptide ratios versus Aβ42 alone. For Aβ42:Aβ40, the effect was reduced by approximately 50% (volume) and 75% (transfer) as compared to Aβ42 alone.
DISCUSSION: Use of Aβ ratios, in conjunction with concentrations, may mitigate confounding factors and assist the clinical diagnostic process for Alzheimer's disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Alzheimer's & dementia (Amsterdam, Netherlands) - 10(2018) vom: 20., Seite 311-321 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Toombs, Jamie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer's disease |
|---|
| Anmerkungen: |
Date Revised 17.03.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.dadm.2018.02.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM284270008 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM284270008 | ||
| 003 | DE-627 | ||
| 005 | 20231225042827.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dadm.2018.02.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0947.xml |
| 035 | |a (DE-627)NLM284270008 | ||
| 035 | |a (NLM)29780875 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Toombs, Jamie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.03.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a INTRODUCTION: We tested the hypothesis that the amyloid β (Aβ) peptide ratios are more stable than Aβ42 alone when biofluids are exposed to two preanalytical conditions known to modify measurable Aβ concentration | ||
| 520 | |a METHODS: Human cerebrospinal fluid (CSF) and culture media (CM) from human cortical neurons were exposed to a series of volumes and polypropylene surfaces. Aβ42, Aβ40, and Aβ38 peptide concentrations were measured using a multiplexed electrochemiluminescence immunoassay. Data were analyzed using mixed models in R | ||
| 520 | |a RESULTS: Decrease of measurable Aβ peptide concentrations was exaggerated in longer peptides, affecting the Aβ42:Aβ40 and Aβ42:Aβ38 ratios. However, the effect size of surface treatment was reduced in Aβ peptide ratios versus Aβ42 alone. For Aβ42:Aβ40, the effect was reduced by approximately 50% (volume) and 75% (transfer) as compared to Aβ42 alone | ||
| 520 | |a DISCUSSION: Use of Aβ ratios, in conjunction with concentrations, may mitigate confounding factors and assist the clinical diagnostic process for Alzheimer's disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer's disease | |
| 650 | 4 | |a Amyloid β ratio | |
| 650 | 4 | |a Cell culture media | |
| 650 | 4 | |a Cerebrospinal fluid | |
| 650 | 4 | |a Preanalytical factors | |
| 650 | 4 | |a Surface adsorption | |
| 700 | 1 | |a Foiani, Martha S |e verfasserin |4 aut | |
| 700 | 1 | |a Wellington, Henrietta |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Ross W |e verfasserin |4 aut | |
| 700 | 1 | |a Arber, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Heslegrave, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Lunn, Michael P |e verfasserin |4 aut | |
| 700 | 1 | |a Schott, Jonathan M |e verfasserin |4 aut | |
| 700 | 1 | |a Wray, Selina |e verfasserin |4 aut | |
| 700 | 1 | |a Zetterberg, Henrik |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's & dementia (Amsterdam, Netherlands) |d 2015 |g 10(2018) vom: 20., Seite 311-321 |w (DE-627)NLM248022180 |x 2352-8729 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2018 |g day:20 |g pages:311-321 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dadm.2018.02.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2018 |b 20 |h 311-321 | ||